Check back often for new updates on our preclinical accelerator and development milestones.

ANN ARBOR, MICHIGAN, August 10th, 2017—TSRL, Inc., a privately-held preclinical accelerator, announced today that the company was awarded a Phase I Small Business Technology Transfer (STTR) grant and a Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy & Infectious Diseases (NIAID) of the National Institute of Health (NIH). TSRL and its collaborators from Purdue University and the University of Washington were awarded $3.6 million over the next three years to develop a portfolio of novel antibacterials for difficult-to-treat infections.

ANN ARBOR, MICHIGAN, February 17, 2017—TSRL, Inc., announced today that the company was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy & Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). TSRL will receive approximately $600,000 over the next two years for the development of a transdermal delivery system of zanamivir (GSK, Relenza®), an inhalation drug product used in the treatment of influenza A & B. This grant, awarded in collaboration with Dr. Audra Stinchcomb’s team at F6 Pharma, explores microneedle delivery strategies of formulations that optimize solubility and absorption of zanamivir through the skin. In addition, TSRL will be accessing NIAID’s preclinical services for pharmacology testing of the transdermal formulation.

Sept. 26th, 2016, Ann Arbor, Michigan: RetroSense Therapeutics, a privately-held biotechnology company developing novel gene therapies for vision restoration, announced that Allergan plc has acquired all assets related to its lead development program in an all-cash transaction. RetroSense’s RST-001 program employs a photosensitivity gene to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration. Neither of these conditions have FDA-approved treatments to improve or restore vision.

Introduction

In July 2004, the Infectious Diseases Society of America (IDSA) released a report called "Bad Bugs, No Drugs." This report identified several species of antibiotic-resistant bacteria that were expected to play a lead role in the next global health crisis to come. The authors cited a high prevalence of drug-resistant infections--362,000 in the US in 2002--and lack of new antibiotics in development as warning signs. Twelve years have passed since the report published, and according to the CDC, >2 million people become infected and >23,000 die from drug-resistant infections every year. A 2009 paper by Boucher et al implicated six actors from their pathology, persistence, and presence in US hospitals: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter, Pseudomonas aeruginosa and Enterobacter. They termed them "ESKAPE" pathogens.

Ann Arbor, Michigan, March 3rd, 2016: TSRL Inc., a preclinical accelerator developing novel anti-infective therapeutics in areas of high unmet medical need, is presenting at the 29th International Conference on Antiviral Research (ICAR) April 17th - 21st at the Hilton La Jolla Torrey Pines hotel in La Jolla, CA.

Dr. Steven King will present on a "Genetically Optimized Banana Lectin for the Treatment of Influenza," and Dr. Eric Simon will present on an analytical method for characterization of BL-84, a genetically optimized therapeutic banana lectin. Furthermore, Dr. Shyamala Ganesan will present on the in vitro potency of nucleoside phosphonate analogues and Dr. Simon will present an LC-MS assay for measuring intracellular concentrations of USC-505, a nuceleoside phosphonate analogue.

Our collaborators Dr. William (Bill) Wold and Dr. Jennifer Moffat will present on the in vivo efficacy of nucleoside analogues in Syrian hamster and mice, respectively. Dr. Wold will present on the protection of immunocompromised Syrian hamsters against type 5 and 6 adenovirus and Dr. Moffat will present on the protection of mice against VZV, otherwise known as herpes zoster or shingles.

TSRL, Inc. is a privately-held, anti-infectives pharmaceutical accelerator focused on the preclinical development of investigator-initiated drug therapy concepts. More information about TSRL, Inc. is available on the company website www.tsrlinc.com or can be requested by contacting Andrew Hertig, Business Development, 734-663-4233 x224, ahertig@tsrlinc.com.

Ann Arbor, Michigan, Sept 15th, 2015: TSRL Inc., a preclinical accelerator developing novel anti-infective therapeutics in areas of high unmet medical need, is presenting at the 2015 AAPS Annual Meeting and Exposition, October 25-29, at the Orange County Convention Center in Orlando Florida.

Dawn Reyna, Sr. Director of Laboratory Services, will be presenting on the "Pharmacokinetics of Potent HPMPA and HPMPC Tyrosinamide Prodrugs with Broad Spectrum Antiviral Activity" and Deanna Mudie, on behalf of the University of Michigan College of Pharmacy, will be presenting on the "Influence of Fluid Shear Rate on the Dissolution Rate of Poorly Soluble Drug Particles; Implications for In Vivo Predictive In Vitro Dissolution Methodologies and Mechanistic Computational Modeling".

TSRL, Inc. is a privately-held anti-infectives drug development firm and accelerator focused on R&D efforts to optimize effectiveness and safety of investigational and marketed therapeutics. More information about TSRL, Inc. is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 734-663-4233 x236, elipka@tsrlinc.com.

Ann Arbor, Michigan, Sept 15th, 2015: TSRL Inc., a preclinical accelerator developing novel anti-infective therapeutics in areas of high unmet medical need, has presented on various topics at the Cutting Edge/Drug Discovery & Development in Michigan Symposium September 9th and 10th.

Eric Simon, PhD presented on the "Development of an LC-MS Assay for Measurement of of Intracellular Concentrations of Cidofovir Prodrug USC-505 and its Metabolites". Shyamala Ganesan, PhD presented on "Improved Intracellular Concentrations of Cidofovir Diphosphate Using an Oral Prodrug Approach". Andrew Hertig, MBA, presented on "The Preclinical Accelerator: A New Model for Drug Development".

TSRL, Inc. is a privately-held anti-infectives drug development firm and accelerator focused on R&D efforts to optimize effectiveness and safety of investigational and marketed therapeutics. More information about TSRL, Inc. is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 734-663-4233 x236, elipka@tsrlinc.com.

Ann Arbor, Michigan, June 26th, 2015: Members of our team at TSRL, Inc. visited the Foundations Preschool of Washtenaw County (http://www.foundations-preschool.org/) last Friday for our annual Day of Caring. The weather couldn't have been better as we were put to work scrubbing floors, ripping out weeds, and staining decks. One of our team members even got a bee sting. They are okay--with the help of an onion to reduce the swelling--and the hard work was worth it for everybody. We were able to make our community preschool a cleaner, happier place for the at-risk children who need a place to learn and grow.

Looking forward to next time!

Learn more about United Way/Day of Caring: http://www.wuway.org/node/778

About Foundations Preschool:

Foundations Preschool prepares children from low income families for future academic and social success while providing their parents opportunities for professional, personal and parental growth.

We Accomplish This By Providing:

A focus on the needs of low-income families

Tuition subsidies based on household income

A researched-based curriculum and teaching methods

Professional and educated staff

Opportunities to strengthen parenting skills through monthly workshops and a true parent/school team approach

Ann Arbor, Michigan, May 14th, 2015: TSRL Inc., a pharmaceutical company developing novel anti-infective therapeutics in areas of high unmet medical need, is pleased to announce that Elke Lipka, PhD, MBA, has presented at the 28th International Conference on Antiviral Research (ICAR) in Rome, Italy. The presentation, entitled "Potent Broad Spectrum Anti-DNA Viral Activity for HPMPA and HPMPC Tyrosinamide Prodrugs", reports on the broad spectrum antiviral activity of acyclic nucleoside phosphonates (ANPs) as useful agents in the treatment of many DNA virus infections.

TSRL, Inc. is a privately-held anti-infectives drug development firm and accelerator focused on R&D efforts to optimize effectiveness and safety of investigational and marketed therapeutics. More information about TSRL, Inc. is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 734 663-4233 x236, elipka@tsrlinc.com.

Ann Arbor, Michigan, September 11th, 2014: Therapeutic Systems Research Laboratories, (TSRL), Inc. is pleased to announce the appointment of Dr. Elke Lipka as President of TSRL and Member of the Board of Directors. Dr. Lipka succeeds the late Dr. John Hilfinger, who led the company over the past ten years, transitioning its focus from formulation development to prodrug design and delivery. Dr. Lipka, who has served as Vice President of Business Development since 2007, has played a pivotal role in the development of TSRL’s existing assets and the evaluation of new project and growth opportunities. She is an experienced drug development professional with 20 year of experience in the pharmaceutical industry including at Warner-Lambert, Esperion Therapeutics and Pfizer. Dr. Lipka holds a PhD from Goethe University, Frankfurt, Germany and an MBA from the University of Michigan.

TSRL, Inc. is a privately held oral drug delivery specialty firm focused on R&D efforts to enhance the targeted delivery of investigational and marketed therapeutics. More detailed information about TSRL is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 734 663-4233 x236, elipka@tsrlinc.com.

Ann Arbor, Michigan, June 24th, 2014: Therapeutic Systems Research Laboratories, Inc. (TSRL), announced today that the company was awarded two Phase I and one Phase II Small Business Innovation Research (SBIR) grants from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The grants are supporting the preclinical research of the company’s broad-spectrum antiviral prodrug program, as well as the development of an antiviral therapeutic for the treatment of adenovirus infections. TSRL will be receiving up to $4.2 million over the next 3 years through these SBIR grants. In addition, initial manufacturing scale up of a lead candidate and preclinical pharmacology testing has been performed for TSRL by NIAID under the NIAID preclinical services contracts program.

TSRL, Inc. is a privately held oral drug delivery specialty firm focused on R&D efforts to enhance the targeted delivery of investigational and marketed therapeutics. More detailed information about TSRL is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, Vice President for Business Development, 734 663-4233 x236, elipka@tsrlinc.com.

Ann Arbor, Michigan, June 12th, 2014: Therapeutic Systems Research Laboratories, (TSRL), Inc. announced today that it has entered into a Termination and Non-Assertion Agreement (the “Agreement”) with Simulations Plus, Inc., a California corporation (“SLP”). Under the terms of the Agreement, SLP and TSRL agreed to terminate the Exclusive Software Licensing Agreement, under which TSRL licensed to SLP Software Technology and Databases in return for royalty payments. SLP will pay TSRL a total consideration of $6 million.

TSRL, Inc. is a privately held oral drug delivery specialty firm focused on R&D efforts to enhance the targeted delivery of investigational and marketed therapeutics. More detailed information about TSRL is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, Vice President of Business Development, 734 663-4233 x236, elipka@tsrlinc.com.

TSRL, Inc.

Based in Ann Arbor, Michigan, TSRL's Technology Accelerator creates value by providing a combination of business and scientific expertise, infrastructure, and wet-lab data to take drug-therapy concepts to business formation or licensing-readiness.